Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Amy K Erbe, Wei Wang, Lakeesha Carmichael, KyungMann Kim, Eneida A Mendonca, Yiqiang Song, Dustin Hess, Wendy B. London, Jacquelyn A Hank, Mitchell B Dicciani, Ralph A Reisfeld, Stephen D Gillies, Michael D. Hogarty, John M. Maris, Julie R. Park, Mehmet Fevzi Ozkaynak, Andrew Lee Gilman, Alice L. Yu, Paul M. Sondel
Institutions: University of Wisconsin–Madison, Boston Children's Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, University of California San Diego, Scripps Research Institute, Children's Hospital of Philadelphia, Seattle Children's Hospital, University of Washington, New York Medical College, Levine Children's Hospital
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2739722676